Our network pharmacology analysis identified key targets—including EGFR, ERBB2, TP53, HDAC6, FGFR1, MMP9, and PDGFRB—that are well known for driving prostate cancer progression independent of AR signaling. Here, MMP9 is linked to prostate carcinoma.